Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

HOPE trial

Saposnik, G., Ray, J.G., Sheridan, P., McQueen, M., and Lonn, E., 2009. Homocysteine-lowering therapy and stroke risk, severity, and disability additional findings from the HOPE 2 trial. Stroke. 40 1365-1372. [Pg.85]

Captopril (Capoten) was the original prototype product, and it was administered three times a day. A once-a-day preparation was subsequently patented and marketed. Prospective multicenter double-blind placebo-controlled clinical trials have repeatedly demonstrated an early and persistent survival benefit with ACE inhibitors in CHE patients. ACE inhibitors were found superior to hydralazine and nitrates in a direct comparison. ACE inhibitors are now clearly the agents of first choice in the pharmacological management of CHE There are also a number of additional reasons to use ACE inhibitors. The HOPE trial and other studies demonstrated additional survival and renal protective benefits of ACE inhibition in diabetic and/or hypertensive patients long before they develop CHE. [Pg.156]

Eikelboom et al. (44) 976 HOPE trial Urinary TxB2 Increase in Ml/stroke/death with increase in TxB ... [Pg.144]

In addition to their benefits in patients with established heart failure, ACE inhibitors also are effective for prevention of heart failure. The SOLVD prevention trial showed that enalapril decreased the risk of hospitalization for worsening heart failure and reduced the composite end point of death and heart failure hospitalization in patients with asymptomatic left ventricular dysfunction. The development of diabetes mellitus, an important risk factor for cardiovascular disease that also increases morbidity and mortality in heart failure patients, is reduced by enalapril in patients with chronic heart failure. In a post-hoc analysis of the Heart Outcomes Prevention Evaluation (HOPE) trial, ramipril reduced the development of new-onset heart failure by nearly 25% in patients with normal EFs and no symptoms of heart failure. ... [Pg.233]

More recent data suggest that all patients with CAD, not just ACS or heart failure patients, benefit from an ACE inhibitor. In the Heart Outcome Prevention Evaluation (HOPE) trial, ramipril significantly reduced the risk of death, MI, or stroke in high-risk patients aged 55 years or older with chronic CAD or with diabetes and one cardiovascular risk factor. The more recent European trial On Reduction Of Cardiac Events With Perindopril In Stable Coronary Artery Disease (EUROPA) extended the benefit of chronic therapy with ACE inhibitors to patients with stable CAD at lower risk of cardiovascular events compared with patients from the HOPE trial. In the EUROPA trial, patients randomized to perindopril experienced a lower risk of the combined end point of cardiovascular death, MI, or cardiac arrest compared with patients randomized to placebo. Therefore, based on the extensive benefit of ACE inhibitors in patients with CAD, their routine use should be considered in all patients following an ACS in the absence of a contraindication. [Pg.311]

The HOPE trial (83) evaluated the use of ramipril compared to placebo in 9,297 high-risk patients, approximately 80% of whom had a history of CAD, and 38% of whom had diabetes. There was a clear benefit to treatment over a mean of five years, including an absolute risk reduction of 2% in death from cardiovascular causes (6.1% versus 8.1%, RR 0.74, P <0.001) and a 2.4% absolute risk reduction in nonfatal MI (9.9% versus 12.3%, RR 0.80, P <0.001). [Pg.74]

Another class of vasoactive agents with demonstrated benefit in secondary MI prevention are the angiotensin-con-verting enzyme (ACE) inhibitors. Several large trials of angiotensin receptor blockers as secondary prevention agents are now also underway. Most of the evidence for benefit from ACE inhibitors has centered on patients with heart failure (59). An exception to this was the Heart Outcomes Prevention Evaluation (HOPE) trial, which excluded patients with ejection fractions <40%, and involved 9297 patients (60). There was a 25% reduction in cardiac mortality in patients receiving the ACE inhibitor ramipril. [Pg.216]

Numerous neuropeptides are beheved to be involved with the transmission or inhibition of pain, and the hope is to utilize this approach as a strategy to induce analgesia. Substance P is reported to be a transmitter of nociceptive impulses (39), and therefore antagonists should be analgesic. Capsaicin [404-86-4], C2gH2yN02, is known to deplete substance P and cause analgesia (40), but its side effects are intolerable. Antagonists to bradykinin [58-82-2], a substance known to induce pain (41), have shown some success in preclinical trials. [Pg.385]

Amongst these are bis(cyclopentadienyl) and bis(y3-diketonate) derivatives, some of which are undergoing clinical trials, in the hope that they will provide more extensive application than cisplatin (pp. 1163-4). [Pg.975]

Several TLR-4 adjuvants for vaccines have been developed to date. An example of these is monopho-sphoryl lipid A (MJPL) a modified version of lipid A found in LPS [4]. It has been used extensively in clinical trials as it is far less toxic than LPS. It is hoped to use MPL in vaccines against infectious diseases, allergies and cancer. Derivatives of MPL have now been... [Pg.1210]

A case study is used here to illustrate the benefits of CATD and to emphasize some of the points we have outlined. The example is of simulation applied to a clinical trial. All aspects of the trial have been deliberately disguised. It is hoped that the benefits and results given here are useful and motivating. [Pg.545]

Levonantradol (8.4) was synthesized with the intention to introduce a basic amino function into the heterocycle in the hope of obtaining water-soluble salts. Although the solubility of the hydrochloride is not good it was possible to get stable aqueous micellar solutions with the aid of emulsifiers [145] and the compound made its way as an injectable into clinical trials, but never was approved. [Pg.34]

It was hoped that the more complete blockade of angiotensin II s AT effects would confer greater long-term efficacy with ARBs compared to ACE inhibitors. However, prospective, randomized trials suggest that the clinical efficacy of ARBs is similar to that of ACE inhibitors for reduction of hospitalizations for HF, sudden cardiac death, and all cause mortality.23-25 Despite poorer suppression of AT2, comparable efficacy of ACE inhibitors may be due to the additional effects on the kallikrein-kinin system. Although ARBs produce hemodynamic and neurohormonal effects similar to those of ACE inhibitors, they are considered second-line therapy due to the overwhelming clinical trial experience with ACE inhibitors. [Pg.47]

HOPE Women s Health, Osteoporosis, Progestin/Estrogen trial... [Pg.777]

In excess of 40 million individuals are now thought to be infected by HIV. In 2001 alone, it was estimated that 3 million people died from AIDS and a further 5 million became infected with the virus. Over 20 million people in total are now thought to have died from AIDS. The worst affected geographical region is the southern half of Africa (Table 13.11). Some 90 per cent of sufferers live in poorer world regions. So far, no effective therapy has been discovered, and the main hope of eradicating this disease lies with the development of safe, effective vaccines. The first such putative vaccine entered clinical trials in 1987 but, thus far, no effective vaccine has been developed. [Pg.408]


See other pages where HOPE trial is mentioned: [Pg.75]    [Pg.770]    [Pg.142]    [Pg.111]    [Pg.205]    [Pg.455]    [Pg.1499]    [Pg.232]    [Pg.392]    [Pg.93]    [Pg.329]    [Pg.426]    [Pg.55]    [Pg.501]    [Pg.931]    [Pg.163]    [Pg.245]    [Pg.68]    [Pg.150]    [Pg.98]    [Pg.113]    [Pg.130]    [Pg.20]    [Pg.565]    [Pg.863]    [Pg.818]    [Pg.104]    [Pg.76]    [Pg.173]    [Pg.343]    [Pg.288]    [Pg.224]    [Pg.101]    [Pg.282]    [Pg.442]    [Pg.147]   
See also in sourсe #XX -- [ Pg.43 , Pg.44 , Pg.46 , Pg.491 , Pg.703 , Pg.759 , Pg.760 ]




SEARCH



© 2024 chempedia.info